Oncomine™ Myeloid RNA Assay GX v2 (Ion Torrent™)

The Ion Torrent Oncomine Myeloid RNA Assay GX v2 is a comprehensive targeted next-generation sequencing (NGS) assay designed for sensitive detection of myeloid disorder-associated RNA fusion transcripts in blood and bone marrow samples. This assay is the RNA component of the Oncomine Myeloid Assay GX v2 (Cat. No. A50694), which includes both DNA and RNA assays. This assay is compatible with the Genexus Integrated Sequencer, which performs library preparation, sequencing, analysis, and reporting in an automated sample-to-result workflow. Depending on the workflow, results can be obtained in as little as a single day.

The Oncomine Myeloid RNA Assay GX v2 features include:
• Comprehensive coverage of >700 key fusion transcripts associated with myeloid disorders
• Automated sample-to-report workflow on the Genexus sequencer in less than a day
• Sequence up to 32 RNA samples on one lane of a GX5 Chip in a single run
• Less than 15 minutes hands-on time

The Oncomine Myeloid RNA Assay GX v2 is designed to assist in myeloid cancer research. The RNA panel includes 30 fusion driver genes covering the most relevant targets associated with major myeloid disorders, including acute myeloid leukemia (AML), myeloid dysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

The multiplex primer design leverages Ion AmpliSeq technology to generate results from multiple samples in a single run. Sequencing results are automatically analyzed by Genexus software using an optimized assay-specific analysis workflow.

The assay kit includes one pool of Ion AmpliSeq oligonucleotide primers and Genexus Strips 1 & 2-AS library reagents, enough to sequence up to 32 RNA samples on the Genexus Integrated Sequencer. One end-to-end sequencing run uses one lane on the GX5 Chip and accommodates up to 32 samples. Additional Genexus sequencer reagents and supplies must be ordered separately.